Science Explorer Back to mapMap
Discussion
Topic · Eosinophilic Disorders and Syndromes

Most cited papers in Eosinophilic Disorders and Syndromes

Eosinophilic Disorders and Syndromes

What are the most cited papers in Eosinophilic Disorders and Syndromes?

The most cited paper in Eosinophilic Disorders and Syndromes is "Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia" (Brian J. Druker, Moshe Talpaz, Debra J. Resta et al., 2001), with 5,296 citations. Next come "Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells" (3,681) and "Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia" (3,593).

Showing 50 of 100 papers. Every paper with more than 857 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia Brian J. Druker, Moshe Talpaz, Debra J. Resta et al. · New England Journal of Medicine Open access 5 Apr 2001 5,296
2 Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells Brian J. Druker, Shu Tamura, Elisabeth Buchdunger et al. · Nature Medicine May 1996 3,681
3 Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Stephen G. O’Brien et al. · New England Journal of Medicine Open access 12 Mar 2003 3,593
4 Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia Brian J. Druker et al. · New England Journal of Medicine Open access 6 Dec 2006 3,508
5 Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis Ross L. Levine et al. · Cancer Cell Open access Apr 2005 3,023
6 Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia Chromosome Brian J. Druker, Charles L. Sawyers, Hagop M. Kantarjian et al. · New England Journal of Medicine Open access 5 Apr 2001 2,735
7 Diagnosis of Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia Gregory M. Marcus et al. · Circulation Open access 19 Feb 2010 2,683
8 Mechanism of Action and In Vivo Role of Platelet-Derived Growth Factor Carl‐Henrik Heldin, Bengt Westermark · Physiological Reviews Review 10 Jan 1999 2,507
9 Role of platelet-derived growth factors in physiology and medicine Johanna Andræ, Radiosa Gallini, Christer Betsholtz · Genes & Development Open access 15 May 2008 2,479
10 Systemic sclerosis Christopher P. Denton, Dinesh Khanna · The Lancet 13 Apr 2017 2,230
11 The American College of Rheumatology 1990 criteria for the classification of churg‐strauss syndrome (allergic granulomatosis and angiitis) Alfonse T. Masi, Gene G. Hunder, J. T. Lie et al. · Arthritis & Rheumatism Aug 1990 2,223
12 Induction of Chronic Myelogenous Leukemia in Mice by the P210 bcr/abl Gene of the Philadelphia Chromosome George Q. Daley, Richard A. Van Etten, David Baltimore · Science Open access 16 Feb 1990 2,196
13 Epstein-Barr virus. Alan B. Rickinson · PubMed 30 Jan 2002 2,185
14 A Method of Trace Iodination of Proteins for Immunologic Studies Patricia J. McConahey, Frank J. Dixon · International Archives of Allergy and Applied Immunology 16 Jul 2009 2,124
15 Eosinophilic esophagitis: Updated consensus recommendations for children and adults Chris Alexander Liacouras et al. · Journal of Allergy and Clinical Immunology Open access 9 Apr 2011 2,091
16 Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia Hagop Kantarjian, Charles L. Sawyers, Andreas Hochhaus et al. · New England Journal of Medicine Open access 28 Feb 2002 2,041
17 Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor Neil P. Shah, Chris Tran, Francis Y. Lee et al. · Science 15 Jul 2004 1,811
18 Dasatinib in Imatinib-Resistant Philadelphia Chromosome–Positive Leukemias Moshe Talpaz, Neil P. Shah, Hagop M. Kantarjian et al. · New England Journal of Medicine Open access 14 Jun 2006 1,789
19 Underlying Causes and Long-Term Survival in Patients with Initially Unexplained Cardiomyopathy Gary Michael Felker, Richard E. Thompson, Joshua M. Hare et al. · New England Journal of Medicine Open access 13 Apr 2000 1,737
20 A Tyrosine Kinase Created by Fusion of the PDGFRA and FIP1L1 Genes as a Therapeutic Target of Imatinib in Idiopathic Hypereosinophilic Syndrome Jan Cools et al. · New England Journal of Medicine Open access 26 Mar 2003 1,706
21 Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia Giuseppe Saglio, Dong‐Wook Kim, Surapol Issaragrisil et al. · New England Journal of Medicine Open access 5 Jun 2010 1,691
22 Eosinophilic Esophagitis in Children and Adults: A Systematic Review and Consensus Recommendations for Diagnosis and Treatment Glenn T. Furuta, Chris Alexander Liacouras, Margaret H. Collins et al. · Gastroenterology ReviewOpen access 9 Aug 2007 1,683
23 Fused transcript of abl and bcr genes in chronic myelogenous leukaemia Emma Shtivelman, Batia Lifshitz, Robert Peter Gale et al. · Nature Jun 1985 1,641
24 Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia Neil P. Shah, John M. Nicoll, Bhushan Nagar et al. · Cancer Cell Open access Aug 2002 1,635
25 Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22 John Groffen, John R. Stephenson, Nora Heisterkamp et al. · Cell 1984 1,630
26 Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: Proposed Modification of the Task Force Criteria Gregory M. Marcus et al. · European Heart Journal Open access 19 Feb 2010 1,621
27 Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Hagop M. Kantarjian, Neil P. Shah, Andreas Hochhaus et al. · New England Journal of Medicine 5 Jun 2010 1,601
28 European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia Andreas Hochhaus et al. · Leukemia Open access 3 Mar 2020 1,556
29 Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial François‐Xavier Mahon, Delphine Réa, Joëlle Guilhot et al. · The Lancet Oncology 20 Oct 2010 1,556
30 An Outbreak of Community-AcquiredPneumocystis cariniiPneumonia Henry Masur, Mary Ann Michelis, Jeffrey Bruce Greene et al. · New England Journal of Medicine 10 Dec 1981 1,436
31 Polymyositis and dermatomyositis Marinos C. Dalakas, Reinhard Hohlfeld · The Lancet Sep 2003 1,421
32 Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial Eugene R. Bleecker, J. Mark FitzGerald, Pascal Chanez et al. · The Lancet 7 Sep 2016 1,411
33 A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia Annelies de Klein, Ad Geurts van Kessel, Gerard C. Grosveld et al. · Nature Dec 1982 1,393
34 Mepolizumab for Prednisone-Dependent Asthma with Sputum Eosinophilia Parameswaran K. Nair, Márcia Margaret Menezes Pizzichini, Melanie Kjarsgaard et al. · New England Journal of Medicine Open access 4 Mar 2009 1,363
35 Nilotinib in Imatinib-Resistant CML and Philadelphia Chromosome–Positive ALL Hagop M. Kantarjian, Francis Joseph Giles, Lydia Wunderle et al. · New England Journal of Medicine Open access 14 Jun 2006 1,348
36 A Role for Uric Acid in the Progression of Renal Disease Duk‐Hee Kang, Takahiko Nakagawa, Lili Feng et al. · Journal of the American Society of Nephrology Dec 2002 1,312
37 THE EOSINOPHIL Marc E. Rothenberg, Simon Patrick Hogan · Annual Review of Immunology Review 5 Nov 2005 1,302
38 Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia Andreas Hochhaus, Richard A. Larson, François Guilhot et al. · New England Journal of Medicine Open access 8 Mar 2017 1,296
39 HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol Wen‐Hung Chung, Wen‐Hung Chung, Lieh-Bang Liou et al. · Proceedings of the National Academy of Sciences Open access 2 Mar 2005 1,295
40 A Clinical Trial of Immunosuppressive Therapy for Myocarditis Jay W. Mason, John B. OʼConnell, Ahvie Herskowitz et al. · New England Journal of Medicine Open access 3 Aug 1995 1,283
41 AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance Thomas O’Hare et al. · Cancer Cell Open access Nov 2009 1,265
42 The development of imatinib as a therapeutic agent for chronic myeloid leukemia Michael W. Deininger, Elisabeth Buchdunger, Brian J. Druker · Blood 23 Dec 2004 1,265
43 New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment Francisco Cervantes, Brigitte Dupriez, Arturo Pereira et al. · Blood Open access 6 Nov 2008 1,259
44 Mast-Cell Infiltration of Airway Smooth Muscle in Asthma Christopher Edward Brightling, Peter Bradding, Fiona A. Symon et al. · New England Journal of Medicine Open access 30 May 2002 1,243
45 Systemic Vasculitis with Asthma and Eosinophilia JOHN G. LANHAM, Keith B. Elkon, Charles Dickson Pusey et al. · Medicine Mar 1984 1,240
46 Frequency of Major Molecular Responses to Imatinib or Interferon Alfa plus Cytarabine in Newly Diagnosed Chronic Myeloid Leukemia Timothy P. Hughes, Jaspal Kaeda, Susan Branford et al. · New England Journal of Medicine Open access 8 Oct 2003 1,223
47 Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases Pablo García‐Pavía et al. · European Heart Journal Open access 2 Feb 2021 1,221
48 Therapeutic Effects of Xanthine Oxidase Inhibitors: Renaissance Half a Century after the Discovery of Allopurinol Pál Pacher, Alex Nivorozhkin, Csaba Szabó · Pharmacological Reviews Open access 28 Feb 2006 1,219
49 Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results Tim Hughes · Blood Open access 7 Mar 2006 1,209
50 Recent Developments in Myofibroblast Biology Boris Hinz, Sem Hin Phan, Victor John Thannickal et al. · American Journal Of Pathology Open access 3 Mar 2012 1,204

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for a field when OpenAlex files it under one of the field's topics; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.